<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388319</url>
  </required_header>
  <id_info>
    <org_study_id>BuZonE</org_study_id>
    <nct_id>NCT04388319</nct_id>
  </id_info>
  <brief_title>Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes</brief_title>
  <acronym>BuZonE</acronym>
  <official_title>Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rose Research Center, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for a Smoke-Free World</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rose Research Center, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-group, small-scale, open-label study (N= 25 to 50) will evaluate the impact of&#xD;
      combination zonisamide and bupropion on the process of switching from combustible cigarettes&#xD;
      (CC) to an e-cigarette. There will be a data collection period of at least five days to&#xD;
      obtain baseline data on use of combustible cigarettes. Participants enrolled in the study&#xD;
      will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette&#xD;
      use, (at V3) participants will be given zonisamide (100 mg/daily) and will begin&#xD;
      extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) in&#xD;
      addition to continued use of the G6. At each visit, participants will receive enough&#xD;
      zonisamide, bupropion, and Halo G6 cartomizers to last until their next study visit. Halo G6&#xD;
      and combination zonisamide and bupropion use will continue until the participant returns for&#xD;
      the End-of-Study visit (V7).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 27, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Actual">June 4, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete switching from combustible cigarettes to Halo G6 e-cigarette</measure>
    <time_frame>Weeks 8-11 post-quit date</time_frame>
    <description>Defined as self-report of no cigarette smoking (not even a puff), confirmed by an expired air CO reading of less than 5 ppm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Point Abstinence from combustible cigarettes</measure>
    <time_frame>Six months post switch day</time_frame>
    <description>Assessed by self-report utilizing an automated SMS messaging system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rewarding effects of smoking combustible cigarettes</measure>
    <time_frame>First week compared to after start of study drugs</time_frame>
    <description>Characterize changes in the two primary scales of the Cigarette Evaluation Questionnaire (mCEQ), assessing smoking satisfaction and psychological reward, compared between cigarettes smoked after meals versus all others smoked during the day, examining how this difference changes after zonisamide/bupropion usage. The mCEQ uses a 7-point scale (0=Not at all; 1=Very little; 2=A little; 3=Moderately; 4=A lot, 5=Quite a lot; 6=Extremely) to measure the following subscales: Satisfaction, Psychological Reward, Enjoyment of Respiratory Tract Sensations, Craving Reduction, Aversion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Combination zonisamide and bupropion with e-cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants enrolled in the study will receive a G6 e-cigarette at V2 for ad libitum use. After the first week of e-cigarette use, (at V3) participants will be given zonisamide and bupropion in addition to continued use of the G6. Use of these study drugs will continue for 12- weeks with a target complete switch date (from combustible cigarettes to e-cigarettes) one week after study drug initiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide</intervention_name>
    <description>Zonisamide (100 mg/daily) for 12 weeks.</description>
    <arm_group_label>Combination zonisamide and bupropion with e-cigarette</arm_group_label>
    <other_name>zonegran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.</description>
    <arm_group_label>Combination zonisamide and bupropion with e-cigarette</arm_group_label>
    <other_name>wellbutrin</other_name>
    <other_name>Zyban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Halo G6 e-cigarette</intervention_name>
    <description>G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.</description>
    <arm_group_label>Combination zonisamide and bupropion with e-cigarette</arm_group_label>
    <other_name>e-cigarette</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has signed the ICF and is able to read and understand the information provided in the&#xD;
             ICF.&#xD;
&#xD;
          2. Is 21 to 65 years of age (inclusive) at screening.&#xD;
&#xD;
          3. Smokes at least 10 commercially available cigarettes per day (no brand restrictions),&#xD;
             for the last 12 months.&#xD;
&#xD;
          4. Has an expired air CO reading of at least 10 ppm at screening.&#xD;
&#xD;
          5. Interested in switching to an electronic cigarette.&#xD;
&#xD;
          6. Willing and able to comply with the requirements of the study.&#xD;
&#xD;
          7. Owns a smart phone with text message and data capabilities compatible with necessary&#xD;
             surveys.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is unhealthy or cannot participate in the study for any reason (e.g., medical,&#xD;
             psychiatric, and/or social reason) as judged by the Investigator or designated medical&#xD;
             staff based on all available assessments from the screening period (e.g., safety&#xD;
             laboratory, vital signs, physical examination, ECG, concomitant medications and&#xD;
             medical history).&#xD;
&#xD;
          2. PHQ-9 score greater than 9, or a score greater than 0 on item #9 (&quot;Thoughts that you&#xD;
             would be better off dead, or of hurting yourself in some way&quot;) at screening.&#xD;
&#xD;
          3. Planned use of an FDA-approved smoking cessation product during the study.&#xD;
&#xD;
          4. High blood pressure (systolic &gt; 150 mmHg or diastolic &gt;95 mmHg) at screening.&#xD;
&#xD;
          5. Body mass index (BMI) less than 15.0 kg/m2 or greater than 40.0 kg/m2.&#xD;
&#xD;
          6. Coronary heart disease, structural cardiac disease (including, but not limited to&#xD;
             valvular heart disease or cardiac murmurs), cardiac dysrhythmias, syncope, cardiac&#xD;
             chest pain, or history of heart attack or heart failure.&#xD;
&#xD;
          7. Has received psychotherapy or behavioral treatments potentially impacting symptoms of&#xD;
             depression, anxiety, or nicotine withdrawal within 30 days of screening, or during the&#xD;
             study.&#xD;
&#xD;
          8. Taking antidepressants, psychoactive medications (e.g. antipsychotics,&#xD;
             benzodiazepines, hypnotics) or medications that prolong QTc.&#xD;
&#xD;
          9. Use of any of these products in the past 30 days:&#xD;
&#xD;
               1. Illegal drugs (or if the urine drug screen is positive for cocaine, THC,&#xD;
                  amphetamines, methamphetamines, or opiates);&#xD;
&#xD;
               2. Experimental (investigational) drugs that are unknown to participant;&#xD;
&#xD;
               3. Chronic opiate use.&#xD;
&#xD;
         10. Use of smokeless tobacco (chewing tobacco, snuff), cigars (except for &quot;Black &amp; Mild&quot;&#xD;
             cigars or Cigarillos), pipes, hookah, e-cigarettes, nicotine replacement therapy or&#xD;
             other smoking cessation treatments within 14 days of screening.&#xD;
&#xD;
         11. Pregnant or nursing (by self-report) or has a positive pregnancy test.&#xD;
&#xD;
         12. Enrollment requirements met.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rose Research Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rose Research Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>e-cigarette</keyword>
  <keyword>zonisamide</keyword>
  <keyword>bupropion</keyword>
  <keyword>combustible cigarettes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zonisamide</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

